Cutera Announces First Patient Treated with FDA Cleared AviClear Acne Device

AviClear uses proprietary technology to deliver safe and effective acne laser treatments with no need for adjunctive pain therapy

Avi360 partnership offers a suite of tools and services for easy integration into dermatology practices

CUTERA, INC. (“Cutera” or the “Company”), a leading provider of dermatology solutions, announced that the first patient outside of clinical trials was treated with AviClear, the only device cleared by the FDA for the treatment of mild, moderate, and severe acne.

Latest Aithority Insights: Momentum Commerce Launches Suite of Amazon Insights Software

AviClear received FDA 510k clearance on March 24, 2022, following the Company’s successful product development process and extensive clinical evaluation. Designed with physician and patient needs in mind, AviClear significantly reduces the severity and frequency of acne following three brief sessions without any adjunctive pain therapy. AviClear rapidly delivers laser energy in combination with AviCool™, a unique handpiece feature that provides unmatched contact cooling capability, delivering a more comfortable treatment experience.

“The patient I treated with the AviClear device has suffered from moderate to severe acne for the past several years and has been seeking a safe, effective, and drug-free treatment option,” said Julie Harper, M.D., Past President of the American Acne and Rosacea Society. “In light of the recent FDA clearance, I advised her that this new treatment option involved no downtime and has had no adverse events throughout its extensive trialing. The AviCool feature allows me to deliver a highly effective treatment without any anesthetic. All of these benefits made my patient very excited to try it.”

Browse The Complete News About Aithority: Sangoma Is Serving Up the Perfect Mix of Communications at Channel Partners

“Now that AviClear treatments have begun, we look forward to partnering with physicians to redefine the acne armamentarium,” said David Mowry, CEO of Cutera. “We are completely focused on eliminating the complexity and administrative burdens associated with current acne treatment options. To deliver on that commitment, we are proud to provide Avi360, a comprehensive practice support program that makes it easier for dermatologists to acquire the system and market it effectively to their patients. From a clinical standpoint, our novel and differentiated approach offers a safer, simpler, and effective solution to this chronic skin condition.”

AviClear is rolling out to physicians throughout the United States over the course of 2022. Doctors and patients are encouraged to visit www.AviClear.com to sign up for updates on product availability and local treatment providers.

Read More About Aithority News : Vuzix Signs Distribution Agreement with Robotiques Cyborg and Receives Initial Smart Glasses Order

 [To share your insights with us, please write to sghosh@martechseries.com]